The dosage of infliximab in the treatment of ankylosing spondylitis: Dollars and sense

A.S. Russell¹, J.H. Orozco², W.P. Maksymowych¹

¹Rheumatic Disease Unit, University of Alberta, Edmonton, Alberta Canada; ²Guadalajara, Mexico.

ABSTRACT
While it seems clear that anti-TNF treatments do improve the clinical condition of patients with ankylosing spondylitis, there is some evidence that doses much smaller than those formally studied in controlled trials may also be very effective, and we would recommend that this aspect be pursued given the overall costs involved.

Key words
Ankylosing spondylitis, infliximab, costs.

Please address correspondence to: Anthony S. Russell, MD, Rheumatic Disease Unit, 562 Heritage Medical Centre, University of Alberta, Edmonton, Alberta T6G 2S2, Canada.

Clin Exp Rheumatol 2002; 20: (Suppl. 28): S135-S136.
© Copyright Clinical and Experimental Rheumatology 2002.